S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Biden To Unleash "Choke Point" Operation On America? (Ad)
Can Carnival Cruise Lines Set Sail For New Highs? 
BioNTech Is Ripe For A Rebound In 2023 
Biden To Unleash "Choke Point" Operation On America? (Ad)
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Banking Nightmare (Ad)
Finland's NATO membership: What's next?
Will Investors Lose Their Shirts Chasing Gap's 6.8% Dividend?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Biden To Unleash "Choke Point" Operation On America? (Ad)
Can Carnival Cruise Lines Set Sail For New Highs? 
BioNTech Is Ripe For A Rebound In 2023 
Biden To Unleash "Choke Point" Operation On America? (Ad)
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Banking Nightmare (Ad)
Finland's NATO membership: What's next?
Will Investors Lose Their Shirts Chasing Gap's 6.8% Dividend?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Biden To Unleash "Choke Point" Operation On America? (Ad)
Can Carnival Cruise Lines Set Sail For New Highs? 
BioNTech Is Ripe For A Rebound In 2023 
Biden To Unleash "Choke Point" Operation On America? (Ad)
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Banking Nightmare (Ad)
Finland's NATO membership: What's next?
Will Investors Lose Their Shirts Chasing Gap's 6.8% Dividend?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Biden To Unleash "Choke Point" Operation On America? (Ad)
Can Carnival Cruise Lines Set Sail For New Highs? 
BioNTech Is Ripe For A Rebound In 2023 
Biden To Unleash "Choke Point" Operation On America? (Ad)
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Banking Nightmare (Ad)
Finland's NATO membership: What's next?
Will Investors Lose Their Shirts Chasing Gap's 6.8% Dividend?
NYSE:EVH

Evolent Health - EVH Stock Forecast, Price & News

$31.41
+0.81 (+2.65%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$30.90
$31.55
50-Day Range
$29.94
$35.80
52-Week Range
$21.83
$39.78
Volume
619,209 shs
Average Volume
970,488 shs
Market Capitalization
$3.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.70

Evolent Health MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
51.9% Upside
$47.70 Price Target
Short Interest
Healthy
4.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of Evolent Health in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$12.49 M Sold Last Quarter
Proj. Earnings Growth
364.29%
From $0.14 to $0.65 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Computer And Technology Sector

234th out of 614 stocks

Management Services Industry

4th out of 7 stocks


EVH stock logo

About Evolent Health (NYSE:EVH) Stock

Evolent Health, Inc. engages in the provision of healthcare delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.

Receive EVH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolent Health and its competitors with MarketBeat's FREE daily newsletter.

EVH Stock News Headlines

Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Evolent Health (NYSE:EVH) Coverage Initiated at StockNews.com
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
EngageSmart (ESMT) Matches Q4 Earnings Estimates
Here’s Why Evolent Health (EVH) Declined in Q4
Cowen & Co. Reaffirms Their Buy Rating on Evolent Health (EVH)
Evolent Health
Evolent Health: A Bit Complex, But Interesting
5 Analysts Have This to Say About Evolent Health
Why Evolent Health Stock Is Soaring Today
See More Headlines
Receive EVH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolent Health and its competitors with MarketBeat's FREE daily newsletter.

EVH Company Calendar

Last Earnings
2/22/2023
Today
3/28/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Management services
Sub-Industry
N/A
Employees
5,100
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$47.70
High Stock Price Forecast
$59.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+51.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-19,160,000.00
Pretax Margin
-4.59%

Debt

Sales & Book Value

Annual Sales
$1.35 billion
Cash Flow
$1.52 per share
Book Value
$8.60 per share

Miscellaneous

Free Float
106,388,000
Market Cap
$3.49 billion
Optionable
Optionable
Beta
1.56

Key Executives

  • Seth B. BlackleySeth B. Blackley
    Chief Executive Officer & Non-Independent Director
  • Dan McCarthy
    President
  • Steven TutewohlSteven Tutewohl
    Chief Operating Officer
  • John Johnson
    Chief Financial Officer
  • John Tam
    Chief Strategy Officer













EVH Stock - Frequently Asked Questions

Should I buy or sell Evolent Health stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVH shares.
View EVH analyst ratings
or view top-rated stocks.

What is Evolent Health's stock price forecast for 2023?

10 brokerages have issued 1-year price targets for Evolent Health's shares. Their EVH share price forecasts range from $32.00 to $59.00. On average, they anticipate the company's stock price to reach $47.70 in the next twelve months. This suggests a possible upside of 51.9% from the stock's current price.
View analysts price targets for EVH
or view top-rated stocks among Wall Street analysts.

How have EVH shares performed in 2023?

Evolent Health's stock was trading at $28.08 on January 1st, 2023. Since then, EVH shares have increased by 11.9% and is now trading at $31.41.
View the best growth stocks for 2023 here
.

Are investors shorting Evolent Health?

Evolent Health saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 5,180,000 shares, a decline of 9.4% from the February 28th total of 5,720,000 shares. Based on an average daily volume of 974,800 shares, the days-to-cover ratio is presently 5.3 days.
View Evolent Health's Short Interest
.

When is Evolent Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our EVH earnings forecast
.

How were Evolent Health's earnings last quarter?

Evolent Health, Inc. (NYSE:EVH) announced its quarterly earnings results on Wednesday, February, 22nd. The technology company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.02. The technology company had revenue of $382.43 million for the quarter, compared to analysts' expectations of $373.68 million. Evolent Health had a positive trailing twelve-month return on equity of 7.50% and a negative net margin of 1.42%.

What guidance has Evolent Health issued on next quarter's earnings?

Evolent Health issued an update on its first quarter 2023 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $420.00 million-$440.00 million, compared to the consensus revenue estimate of $410.36 million.

What is Seth Blackley's approval rating as Evolent Health's CEO?

12 employees have rated Evolent Health Chief Executive Officer Seth Blackley on Glassdoor.com. Seth Blackley has an approval rating of 100% among the company's employees. This puts Seth Blackley in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Evolent Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include CA (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Advanced Micro Devices (AMD), Energy Transfer (ET), Chipotle Mexican Grill (CMG), Ford Motor (F), Cisco Systems (CSCO) and Heron Therapeutics (HRTX).

When did Evolent Health IPO?

(EVH) raised $150 million in an initial public offering (IPO) on Friday, June 5th 2015. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

What is Evolent Health's stock symbol?

Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."

Who are Evolent Health's major shareholders?

Evolent Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (3.23%), Granahan Investment Management LLC (3.14%), Engaged Capital LLC (2.75%), Dimensional Fund Advisors LP (2.51%), Credit Suisse AG (2.32%) and Fred Alger Management LLC (1.87%). Insiders that own company stock include Cheryl Scott, Frank J Williams, Frank J Williams, John Paul Johnson, Jonathan Weinberg, Mary Bridget Duffy, Seth Blackley, Simon Maisey and Steve Tutewohl.
View institutional ownership trends
.

How do I buy shares of Evolent Health?

Shares of EVH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evolent Health's stock price today?

One share of EVH stock can currently be purchased for approximately $31.41.

How much money does Evolent Health make?

Evolent Health (NYSE:EVH) has a market capitalization of $3.49 billion and generates $1.35 billion in revenue each year. The technology company earns $-19,160,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.

How many employees does Evolent Health have?

The company employs 5,100 workers across the globe.

How can I contact Evolent Health?

Evolent Health's mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The official website for the company is www.evolenthealth.com. The technology company can be reached via phone at (571) 389-6000, via email at investorrelations@evolenthealth.com, or via fax at 571-389-6001.

This page (NYSE:EVH) was last updated on 3/28/2023 by MarketBeat.com Staff